Login to Your Account

One Down; One to Go: Zalicus Bust Leaves Pain Bid Standing

By Randy Osborne
Staff Writer

Monday, November 11, 2013
Something of a mystery surrounds the Phase II dashed hopes with Zalicus Inc.’s oral calcium channel blocker Z160, which missed its primary endpoints in two pain indications, testing patients with lumbosacral radiculopathy and postherpetic neuralgia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription